USPTO serial 88294201
G
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 9, 2024
- Examiner
- SABAGH, LAILA TAREK
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with G?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
MATTHEW WARNER-BLANKENSHIP
MATTHEW WARNER-BLANKENSHIP Dentons Davis Brown215 10th Street, Suite 1300Des Moines, IA 50309UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Advertising the goods and services of others focused on the application of personal genetic information for pain management, mental health and other comorbid conditions; developing promotional campaigns focused on the application of personal genetic information for pain management, mental health and other comorbid conditions, and marketing services, namely, marketing consultancy for businesses in the field of personal genetic information for pain management, mental health and other comorbid conditions, all the foregoing not including veterinary or plant applications | ACTIVE | — |
| 041 | Providing online non-downloadable audio and video recordings containing information in the field of medical testing services, namely, genetic testing and genetic screening over a global computer network | ACTIVE | — |
| 042 | Genetic testing and genetic screening services for scientific research purposes; scientific research in the fields of genomics and genetics; scientific research in the application of personal genetic information with respect to medical or nutritional treatments, pharmaceuticals and clinical trials; providing genetic-based nutritional and pharmaceutical research information via the internet and via printed publications; providing clinical laboratory testing services, namely, pharmacogenetic tests, gene sequencing-based tests and genotyping based on the assessment, development and application of human genomic discoveries in the pharmaceutical, informatics and human clinical diagnostic industries, all the foregoing not including veterinary or plant applications; medical research in the fields of genomics and genetics; providing genetic-based medical research information via the internet and via printed publications; medical research in the fields of pharmacogenomics and pharmacogenetics; providing temporary use of on-line non-downloadable software applications related to medical conditions addressed by medical testing services, namely, platform as a service (PAAS) featuring computer software and mobile device applications for accessing information in the field of pain management, mental health and other comorbid conditions; providing genetic testing information for patients and healthcare professionals via an internet website portal; online services relating to medical testing services, namely, providing genetic testing and genetic screening information for patients and healthcare professionals via an internet website portal | ACTIVE | — |
| 044 | Medical diagnostic testing services and providing medical information in the form of personalized reports online in the field of genetic testing for medical purposes; providing clinical laboratory testing services, namely, personalized medical tests based on the assessment, development and application of human genomic discoveries in the medical industry; online medical testing services, namely, genetic testing and genetic screening; Medical information services, namely, providing personalized information online in the field of genetic testing for medical purposes; medical information services, namely, reporting and providing feedback to patients and healthcare professionals on pharmacogenetic testing service results and relevance to medical and nutritional treatments, namely, personal genetic information for pain management, mental health and other comorbid conditions and for understanding individual responses to medication, all the foregoing not including veterinary or plant applications; medical information services, namely, analyzing pharmacogenetic testing service results and relevance to medical and nutritional treatments, namely, the interaction between personal genetic information and pharmaceuticals, all the foregoing not including veterinary or plant applications; medical information services, namely, preparation of reports on pharmacogenetic testing service results and relevance to medical and nutritional treatments, namely, analyzing individual pharmacogenetics and the interaction between personal genetic information and pharmaceuticals, all the foregoing not including veterinary or plant applications | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Inagene Diagnostics Inc.
- Other trademarks owned by Inagene Diagnostics Inc.
- Other trademarks owned by Inagene Diagnostics Inc.
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named G
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 9, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 9, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 24, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 24, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 4, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 18, 2023 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Sep 15, 2023 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Sep 8, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 7, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 6, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 6, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 6, 2023 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 6, 2023 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 6, 2023 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Feb 15, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 15, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 14, 2023 | ALIE | ASSIGNED TO LIE | — |
| Feb 6, 2023 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Aug 6, 2022 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Aug 6, 2022 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Aug 6, 2022 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jul 7, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 7, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 16, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 16, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 16, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 10, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 10, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 10, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 10, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 10, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 10, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 10, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 10, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 2, 2020 | ALIE | ASSIGNED TO LIE | — |
| Nov 2, 2020 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| May 1, 2020 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| May 1, 2020 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| May 1, 2020 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Nov 1, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 1, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 1, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 28, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 28, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 23, 2019 | ALIE | ASSIGNED TO LIE | — |
| Oct 17, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 24, 2019 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Sep 24, 2019 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Sep 24, 2019 | EPEN | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | — |
| Sep 24, 2019 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Aug 3, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 2, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 2, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 25, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 21, 2019 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Mar 2, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 12, 2019 | NWAP | NEW APPLICATION ENTERED | — |